US20040242504A1 - Novel composition and method for the treatment of hypertension - Google Patents

Novel composition and method for the treatment of hypertension Download PDF

Info

Publication number
US20040242504A1
US20040242504A1 US10/449,828 US44982803A US2004242504A1 US 20040242504 A1 US20040242504 A1 US 20040242504A1 US 44982803 A US44982803 A US 44982803A US 2004242504 A1 US2004242504 A1 US 2004242504A1
Authority
US
United States
Prior art keywords
quercetin
atii
gel
composition
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/449,828
Inventor
Vadim Ivanov
Svetlana Ivanova
Waheed Roomi
Aleksandra Niedzwiecki
Matthias Rath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/449,828 priority Critical patent/US20040242504A1/en
Priority to JP2006533488A priority patent/JP2007520449A/en
Priority to BRPI0410868-0A priority patent/BRPI0410868A/en
Priority to AU2004245017A priority patent/AU2004245017A1/en
Priority to CA002524381A priority patent/CA2524381A1/en
Priority to PCT/US2004/016902 priority patent/WO2004108127A1/en
Priority to ZA200509139A priority patent/ZA200509139B/en
Priority to RU2005141423/13A priority patent/RU2005141423A/en
Priority to EP04753685A priority patent/EP1628658A4/en
Priority to CNA200480015142XA priority patent/CN1798555A/en
Priority to MXPA05012859A priority patent/MXPA05012859A/en
Priority to YUP-2005/0887A priority patent/RS20050887A/en
Priority to KR1020057022975A priority patent/KR20060014067A/en
Priority to US10/855,111 priority patent/US7166309B2/en
Priority to UAA200511385A priority patent/UA82879C2/en
Publication of US20040242504A1 publication Critical patent/US20040242504A1/en
Priority to NO20056193A priority patent/NO20056193L/en
Assigned to RATH, MATTHIAS reassignment RATH, MATTHIAS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NIEDZWIECK, ALEKSANDRA, IVANOV, VADIM, IVANOVA, SVETLANA, ROOMI, WAHID M.
Priority to US11/672,268 priority patent/US20070141171A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to a pharmacological composition and method that provides for reduction of blood pressure using natural compounds.
  • This composition is preferably used for patients susceptible to or suffering from blood pressure elevated above normal range.
  • angiotensin II i.e. inhibitors of Angiotensin Converting Enzyme (ACE) which block a conversion of angiotensin I to angiotensin II by arterial wall cells
  • ACE Angiotensin Converting Enzyme
  • Both classes of compounds are being tested in experimental conditions for their capacity to block angiotensin-dependent contraction of arterial wall either using arteries isolated from laboratory animals or a model of cultured smooth muscle cells embedded in collagen gel.
  • a capacity of a tested compound to block a conractile activity of angitensin II in such experimental models unequivocally means that this compound will block angiotensin II activity in in vivo conditions and will reduce angiotensin-driven abnormally high blood pressure.
  • the present invention provides for a composition and method of treatment and prevention of hypertension and its resulting complications comprising the step of administering to a patient a therapeutically-effective amount of Quercetin or Quercetin Glycosides and Epican Forte in therapeutic proportions.
  • Quercetin Glycosides extracted from a plant source, including but not limiting to the group of onions and apples.
  • the dose of Quercetin is equivalent to between approximately 100 mg and 15 grams on a daily basis. More preferably, the dose of Quercetin is equivalent to between approximately 1 grams and 10 grams on a daily basis. It is understood that the dose of Quercetin is repeated daily.
  • Quercetin is optionally administered orally to a human as part of foods, drinks, health bars, bread or cereals.
  • the dosage of Epican Forte and the ingredients therein is administered in daily amounts indicated in Table 1.
  • FIG. 1 is a graph showing the effects of Angiotensin II and Thrombin on SMC Gel Contraction in control groups and in the presence Epican Forte.
  • FIG. 2 shows the effect of 0.1 U/ml Thrombin and 100 mcg/ml of Epican Forte.
  • FIG. 3 shows SMC gel contraction by 1 mcM Angiotensin II and the effect of Epican Forte.
  • FIGS. 4 and 5 show SMC gel contraction by Angiotensin II.
  • FIGS. 6, 7, and 8 respectively compare SMC gel contraction by Angiotensin II in presence of the three groups of Epican Forte, Arginine and Ascorbate, and Ca++ and Mg++.
  • FIG. 9 shows SMC gel contraction by Angiotensin I and II and the effect of 100 mcg/ml of Epican Forte.
  • FIG. 10 shows SMC gel contraction by Angiotensin II and the effects of Resveratrol and Genistein.
  • FIG. 11 shows SMC gel contraction by Angiotensin II and the effect of Relacor.
  • FIG. 12 shows SMC gel contraction by Angiotensin II and N-Acetyl Cystein.
  • FIG. 13 shows SMC gel contraction by Angiotensin II at 1 mcM and the effect of Relacor.
  • FIG. 14 shows SMC gel contraction by Angiotensin II at 1 mcM and the effects of Lysine and Proline.
  • FIG. 15 shows SMC gel contraction by Thrombin.
  • FIG. 16 shows SMC gel contraction by Angiotensin II.
  • FIG. 17 shows SMC gel contraction by Thrombin.
  • FIG. 18 shows SMC gel contraction by Angiotensin II.
  • FIG. 19 shows SMC gel contraction
  • FIG. 20 shows SMC gel contraction and the effects of Catechins.
  • FIG. 21 shows SMC gel contraction and the effects of Polyphenols.
  • Bioflavonoids have been recognized to support arterial wall structural integrity and interfere with a variety of pro-atherosclerotic stimuli.
  • SMC cultured human aortic smooth muscle cells
  • Ang II angiotensin II
  • Gel contraction was stimulated by addition of 1 micromol/L angiotensin II (Ang II) in serum-free media and the gel area was assessed by digital image analysis after 24 hours.
  • EGCG epigallocatechin gallate
  • Que quercetin
  • a therapeutically effective amount of Quercetin is defined primarily by clinical response in a patient, and ranges from about an equivalent of 100 mg to 15 grams daily on variable schedule. A more preferred range of an effective amount of Quercetin is between about an equivalent of approximately 1 grams to 10 grams daily on a variable schedule. Preferably the dose of Quercetin is repeated daily to achieve the desired effect. Quercetin also can derive from Quercetin Glycosides, naturally occurring bioflavonoids, thus Quercetin Glycosides are optionally administered orally in place of Quercetin together with the ingredients of Epican Forte.
  • SMC vascular smooth muscle cells isolated from human aorta. Cells are used from 4 th to 8 th passages.
  • bioflavonoids participate in the regulation of SMC-mediated contraction and that they have a strong potential in counteracting pathophysiological effects of Angiotensin II. While not being bound by a particular mechanism, Bioflavonoid activity strongly depends on structural characteristics and it is the conception of the present inventors that it is related to extracellular matrix integrity.
  • the present invention provides a treatment, which is directed to reversing and minimizing the lack of sensitivity of arteries that lead to hypertension.
  • Second the present invention provides a treatment that is directed to retarding adverse effects of stimuli, which lead to contraction of smooth muscle cells, which increase blood pressure and results in chronic hypertension.
  • the present invention provides treatment of hypertension, using compounds and extracts from nature, which are less expensive than pharmaceutical compositions.

Abstract

The present invention provides for a composition and method of treatment and prevention of hypertension and its resulting complications comprising the step of administering to a patient a therapeutically-effective amount of Quercetin or Quercetin Glycoside and Epican Forte in therapeutic proportions.

Description

    FIELD
  • This invention relates to a pharmacological composition and method that provides for reduction of blood pressure using natural compounds. This composition is preferably used for patients susceptible to or suffering from blood pressure elevated above normal range. [0001]
    • BACKGROUND
  • The various pathophysiological and clinical effects of hypertension or elevated blood pressure are well documented. These effects have both short term effects resulting in poor health and bad work performance, and longer term effects which includes myocardial infarction, stroke, cardiac arrest, kidney disease, kidney failure and others. Moreover, the effect of hypertension is exacerbated in conjunction with other diseases such as diabetes, etc. In recent years it is estimated that more than 50% of deaths relating to cardiovascular disease in the United States alone was related to or resulted from high blood pressure. Additionally, high blood pressure is the most common cause of cardiac failure or other disease states requiring some amount of hospitalization. [0002]
  • There has been significant and extensive research for effective long-term treatment for hypertension. However, present treatments for such disorders are partial treatments such as administration of Angiotensin Converting Enzyme inhibitors (ACE inhibitors), and other pharmaceutical agents. These treatments have serious shortcomings in long-term effectiveness, most notable the cost associated with these treatments and significant adverse effects. [0003]
  • There is a vast number of published research done with regard to the mechanisms of pathogenesis of hypertension. It is well accepted that extensive production and extensive activity of angiotensin II are the major source of the development of hypertension, since its excess causes abnormally strong contraction of arteries, compromises process of arteries relaxation and lead therefore to elevated blood pressure. Thus, a massive effort is being undertaken to develop pharmaceutical compounds capable either to reduce formation of angiotensin II (i.e. inhibitors of Angiotensin Converting Enzyme (ACE) which block a conversion of angiotensin I to angiotensin II by arterial wall cells) or to block a biological activity of angiotensin II (i.e. agonists of angiotensin receptors). Both classes of compounds are being tested in experimental conditions for their capacity to block angiotensin-dependent contraction of arterial wall either using arteries isolated from laboratory animals or a model of cultured smooth muscle cells embedded in collagen gel. A capacity of a tested compound to block a conractile activity of angitensin II in such experimental models unequivocally means that this compound will block angiotensin II activity in in vivo conditions and will reduce angiotensin-driven abnormally high blood pressure. [0004]
  • In view of the foregoing, there is a significant need for a pharmacological composition and method that is directed towards treating the underlying hypertension disease process, and towards preserving and restoring the sensitivity of the arteries to stimuli which would allow for proper contraction and relaxation of smooth muscle cells in the arteries. [0005]
  • It is an objective of the present invention to provide a treatment, which is directed to reversing and minimizing the lack of sensitivity of arteries, which lead to hypertension. [0006]
  • It is another objective of the present invention to provide a treatment that is directed to retarding adverse effects of stimuli, which lead to contraction of smooth muscle cells, which increase blood pressure and results in chronic hypertension. [0007]
  • It is yet another objective of the present invention treatment of hypertension, using compounds and extracts from nature which are less expensive and more safe than pharmaceutical compositions. [0008]
    • SUMMARY
  • The present invention provides for a composition and method of treatment and prevention of hypertension and its resulting complications comprising the step of administering to a patient a therapeutically-effective amount of Quercetin or Quercetin Glycosides and Epican Forte in therapeutic proportions. As an option, Quercetin Glycosides extracted from a plant source, including but not limiting to the group of onions and apples. Further as an option, the dose of Quercetin is equivalent to between approximately 100 mg and 15 grams on a daily basis. More preferably, the dose of Quercetin is equivalent to between approximately 1 grams and 10 grams on a daily basis. It is understood that the dose of Quercetin is repeated daily. As part of the invention, Quercetin is optionally administered orally to a human as part of foods, drinks, health bars, bread or cereals. The dosage of Epican Forte and the ingredients therein is administered in daily amounts indicated in Table 1.[0009]
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 is a graph showing the effects of Angiotensin II and Thrombin on SMC Gel Contraction in control groups and in the presence Epican Forte. [0010]
  • FIG. 2 shows the effect of 0.1 U/ml Thrombin and 100 mcg/ml of Epican Forte. [0011]
  • FIG. 3 shows SMC gel contraction by 1 mcM Angiotensin II and the effect of Epican Forte. [0012]
  • FIGS. 4 and 5 show SMC gel contraction by Angiotensin II. [0013]
  • FIGS. 6, 7, and [0014] 8 respectively compare SMC gel contraction by Angiotensin II in presence of the three groups of Epican Forte, Arginine and Ascorbate, and Ca++ and Mg++.
  • FIG. 9 shows SMC gel contraction by Angiotensin I and II and the effect of 100 mcg/ml of Epican Forte. [0015]
  • FIG. 10 shows SMC gel contraction by Angiotensin II and the effects of Resveratrol and Genistein. [0016]
  • FIG. 11 shows SMC gel contraction by Angiotensin II and the effect of Relacor. [0017]
  • FIG. 12 shows SMC gel contraction by Angiotensin II and N-Acetyl Cystein. [0018]
  • FIG. 13 shows SMC gel contraction by Angiotensin II at 1 mcM and the effect of Relacor. [0019]
  • FIG. 14 shows SMC gel contraction by Angiotensin II at 1 mcM and the effects of Lysine and Proline. [0020]
  • FIG. 15 shows SMC gel contraction by Thrombin. [0021]
  • FIG. 16 shows SMC gel contraction by Angiotensin II. [0022]
  • FIG. 17 shows SMC gel contraction by Thrombin. [0023]
  • FIG. 18 shows SMC gel contraction by Angiotensin II. [0024]
  • FIG. 19 shows SMC gel contraction. [0025]
  • FIG. 20 shows SMC gel contraction and the effects of Catechins. [0026]
  • FIG. 21 shows SMC gel contraction and the effects of Polyphenols.[0027]
    • DETAILED DESCRIPTION
  • Plant-derived bioflavonoids have been recognized to support arterial wall structural integrity and interfere with a variety of pro-atherosclerotic stimuli. We tested whether bioflavonoids have an effect on the contractile activity of cultured human aortic smooth muscle cells (SMC) embedded in a three-dimensional type I collagen (1 mg/mL) matrix. Gel contraction was stimulated by addition of 1 micromol/L angiotensin II (Ang II) in serum-free media and the gel area was assessed by digital image analysis after 24 hours. Epigallocatechin gallate (EGCG) and quercetin (Que) were the most active inhibitors of gel contraction among the various bioflavonoids tested. When added at the concentration of 30 micromol/L, EGCG and Que inhibited Ang II-induced gel contraction by 97% and 120%, respectively. In comparative analysis of structure-related activity the presence of gallic acid residues in the catechin molecule was shown to enhance its activity. In addition, glycosylation of Que dramatically reduced its capacity to inhibit gel contraction. Comparison of gel contraction inhibition by mixed bioflavonoids extracted from natural sources demonstrated that anti-contractile activity gradually increased from citrus fruits to grape seeds to pine bark to green tea. Inhibition of gel contraction by bioflavonoids did not depend on antioxidant activity, since ascorbic acid was not significantly active in this assay. However, a reduction in Ang II-stimulated gel contraction strongly correlated with a decrease in [0028] matrix metalloproteinase 2 expression by SMC assayed by zymography in cell culture media.
  • A therapeutically effective amount of Quercetin is defined primarily by clinical response in a patient, and ranges from about an equivalent of 100 mg to 15 grams daily on variable schedule. A more preferred range of an effective amount of Quercetin is between about an equivalent of approximately 1 grams to 10 grams daily on a variable schedule. Preferably the dose of Quercetin is repeated daily to achieve the desired effect. Quercetin also can derive from Quercetin Glycosides, naturally occurring bioflavonoids, thus Quercetin Glycosides are optionally administered orally in place of Quercetin together with the ingredients of Epican Forte. [0029]
    • Experimental Protocol
  • The following starting material and equipment were used. [0030]
  • 1. Cultured vascular smooth muscle cells (SMC) isolated from human aorta. Cells are used from 4[0031] th to 8th passages.
  • 2. Human collagen type I. [0032]
  • 3. Angiotensin II. [0033]
  • 4. Epican Forte (composition shown in Table 1, available from Matthias Rath, Inc., and all ingredients commercially available) [0034]
  • 5. Epigallocatechin gallate (EGCG) [0035]
  • 6. Quercetin (chemical structure is well defined) [0036]
  • 7. Cell culture medium (DMEM) [0037]
  • 8. 24 well plastic cell culture plate pre-incubated with 2 mg/ml bovine serum albumin. [0038]
  • 9. Digital camera [0039]
  • 10. Digital image analyzing software (Scion Corporation). [0040]
  • 11. Zymography gel electrophoresis assay (Novorex Corp). [0041]
  • 12. Relacor (composition shown in Table 2, available form Matthias Rath, Inc., and all ingredients commercially available) [0042]
    TABLE 1
    Epican Forte
    Compound Dosage per day
    L-Lysine 1,000 mg
    L-Proline 750 mg
    L-Arginine 500 mg
    Vitamin C, as ascorbic acid, 710 mg
    Calcium Ascorbate, magnesium
    Ascorbate or Ascorbyl Palmitate
    Magnesium
    50 mg
    Standardized Green Tea Extract, 1,000 mg
    80% polyphenils - 800 mg
    (decaffeinated)
    N-Acetyl-Cystein 200 mg
    Selenium
    30 mcg
    Copper
    2 mg
    Manganese
    1 mg
  • [0043]
    TABLE 2
    Relacor
    Compound Dosage per day
    L-Arginine 750 mg
    Vitamin C, as ascorbic acid, 1,000 mg
    Calcium Ascorbate, magnesium
    Ascorbate or Ascorbyl Palmitate
    Magnesium 400 mg
    Vitamin E
    100 IU
    Calcium
    200 mg
    Citrus Fruit Peel Bioflavonoids 100 mg
    • Method
  • Confluent culture of SMC and suspended from culture flask by trypsinization and washed with phosphate-buffered saline (PBS) from serum-containing medium. Cell concentration in suspension was brought to 500,000 cell per mL in serum-free DMEM. Cell suspension was then mixed 1:1 with ice-cold 2 mg/ml collagen type I solution in PBS. Final concentration of collagen was 1 mg/mL, final cell concentration is 250,000 per mL. Collagen-SMC suspension was distributed by 300 microL to the wells of 24 well plate in such a manner to cover the entire bottom surface of the well. The plate was then incubated for one hour at 37° C. to allow gel to polymerize. 0.5 mL of experimental serum-free medium contaning no additions (control), or 1 micromol/L angiotensin II with or without tested bioflavonoid was added to polymerized gel, plate was then gently tapped on the side to detach gel from the bottom of plastic well, and plate was then placed to incubator with the controlled atmosphere containing 5% CO2 at 37° C. for incubation. After 24 hour incubation plate was taken from the incubator and plate image with floating gels was taken using digital camera. Gel flat surface area is measured with digital image analyzing software. Sample of cell culture media was taken for analysis of matrix metalloproteinases activity by zymography (Novorex Corp). Experiments were performed in triplicates and results are presented as a mean +/−SD. [0044]
    • Summary
  • 1. 3-07-03 [0045]
  • a. [0046] ATII 1 mcM and Thrombin 0.1 U/mL no effects
  • b. [0047] EF 100 mcg/ml reduction in contraction from 70% to 55% from the original.
  • 2. 3-10-03 [0048]
  • a. Thombin 0.1 U/mL reduced gel by 58% vs 9% in control [0049]
  • b. [0050] EF 100 mcg/ml+Thrombin gel reduction by 12%
  • 3. 3-11-03 [0051]
  • a. [0052] ATII 1 mcM gel reduction to 59% of Control 100%
  • b. EF dose dependent decrease in gel reduction back to control at 3.7-100 mcg/ml [0053]
  • 4. 3-18-03 [0054]
  • a. [0055] ATII 1 mcM gel reduction to 23% of 100% control
  • b. ATII+[0056] EF 100 mcg/ml 101%
  • c. [0057] ATII+AsA 100 mcM reduction to 30%
  • d. ATII+[0058] EGCG 15 mcM reduction to 30%
  • e. ATII+EGCG+AsA reduction to 33% [0059]
  • 5. 3-20-03 [0060]
  • a. [0061] ATII 1 mcM gel reduction to 81% of 100% control
  • b. ATII+EF(11-33-100 mcg/ml) 1945, 226%, 317% of 100% ATII [0062]
  • c. AsA 0.5 mM+ATII gel reduction to 90% vs 100[0063] % ATII 1 mcM
  • d. Arginine 0.5-2 mM no significant effect on ATII-induced gel reduction [0064]
  • e. ATII+Arginine+AsA 0.5 mM no significant diff. Vs ATII+AsA [0065]
  • f. Ca and Mg 1-4 mM individual or comb no effects on ATII-induced gel [0066]
  • 6. 3-25-03 [0067]
  • a. ATII 110-330-1000 nM dose dependent reduction in gel [0068]
  • b. [0069] EF 100 mcg/ml inhibits gel contraction to less than control at all ATII concentrations
  • c. ATI 330-1000 nM gel reduction at 1000 nM only [0070]
  • d. [0071] EF 100 inhibit gel contraction to less than control values at all ATI concentration
  • e. [0072] EF 100 increased gel area by 48% vs ATII 1 mcM
  • f. Genistein at 30 mcM increased gel area (GA) by 34% alone and by 11% in combination with EF vs ATII [0073]
  • g. Resveratrol at 15 mcM no effect alone not on EF effect [0074]
  • h. Resveratrol at 30 mcM increased GA by 45% alone and by 104% with EF vs ATII [0075]
  • i. 15Resv+15Gen increase by 28% and by 83% with EF vs ATII. [0076]
  • 7. 3-26-03 [0077]
  • a. EF33 returned GA to 100% from 21% reduction by [0078] ATII 1 mcM
  • b. Relacor 3-100 mcg/ml had no effect [0079]
  • c. [0080] Genist15+Relacor 11 had no effect
  • d. [0081] Resver15+Relacor 11 had no effect
  • e. NAC at 2 mcM returned GA to control 100% vs 21 % reduction with ATII, but did not have any effect at higher concentration up to 60 mcM [0082]
  • f. [0083] NAC 20+Rel 11 or NAC20+EF11 had no effect on ATII
  • 8. 3-28-03 [0084]
  • a. Relacor gradually increased GA reduction by ATII at concentration from 11 to 900 mcg/ml with 27% add at 900 [0085]
  • b. Lysine and Proline did not effect ATII GA reduction at 0.25-1 mM [0086]
  • 9. 4-02-03 [0087]
  • a. Thrombin reduced GA by 30% at 1 mcM [0088]
  • b. [0089] AsA 200 mcM had no effect on Thrombin
  • c. EF100 restored GA to 163% vs 100% control [0090]
  • d. EGCG30 mcM restored GA to 206% vs 100% control [0091]
  • e. Resveratrol30 mcM restored GA to 106% vs 100% control [0092]
  • f. Genistein30 mcM restored GA to 78% vs 100% control from 70% Thrombin [0093]
  • g. Querctin30 mcM restored GA to 133% vs 100% control [0094]
  • h. Rutin30 mcM reduced GA to 56% vs 70% Thrombin alone from 100% control [0095]
  • i. Grape seed extract 25 mcg/ml increased GA to 87% from 70% Thrombin alone [0096]
  • j. Picnogenol 25 mcg/ml increased GA to 103% from 70% Thrombin alone [0097]
  • 10.4-02-03 [0098]
  • a. ATII reduced GA by 24% at 1 mcM [0099]
  • b. [0100] AsA 200 mcM had no effect on ATII
  • c. EF100 restored GA to 150% vs 100% control [0101]
  • d. EGCG30 mcM restored GA to 150% vs 100% control [0102]
  • e. Resveratrol30 mcM restored GA to 88% vs 100% control [0103]
  • f. Genistein30 mcM restored GA to 96% vs 100% control from 76% ATII [0104]
  • g. Quercetin30 mcM restored GA to 167% vs 100% control [0105]
  • h. Rutin30 mcM restored GA to 80 vs 76% ATII alone from 100% control [0106]
  • i. Grape seed extract 25 mcg/ml increased GA to 86% from 76% ATII alone [0107]
  • j. Picnogenol 25 mcg/ml increased GA to 105% from 76% ATII alone [0108]
  • 11.4-17-03 [0109]
  • a. EGCG dose-dependently reduced gel contraction by ATII at 3.3-10-30 mcM [0110]
  • b. AsA at 500 mcM did not have effect on ATII-induced gel reduction alone or in combination with 10 EGCG [0111]
  • c. EGCG30 was more effective than ECG30 more effective than EC=C at 30 on ATII-induced gel contraction. [0112]
  • d. Querc30=>Genist30=>Resver30=>Rutin30 on ATII [0113]
  • The results show that bioflavonoids participate in the regulation of SMC-mediated contraction and that they have a strong potential in counteracting pathophysiological effects of Angiotensin II. While not being bound by a particular mechanism, Bioflavonoid activity strongly depends on structural characteristics and it is the conception of the present inventors that it is related to extracellular matrix integrity. [0114]
  • It is therefore evident how the objective of the present invention is satisfied. First, the present invention provides a treatment, which is directed to reversing and minimizing the lack of sensitivity of arteries that lead to hypertension. [0115]
  • Second the present invention provides a treatment that is directed to retarding adverse effects of stimuli, which lead to contraction of smooth muscle cells, which increase blood pressure and results in chronic hypertension. [0116]
  • Third, the present invention provides treatment of hypertension, using compounds and extracts from nature, which are less expensive than pharmaceutical compositions. [0117]

Claims (14)

The following is claimed:
1. A method for treatment and/or prevention of hypertension comprising the step of administering to a patient a therapeutically-effective amount of Quercetin or Quercetin Glycosides, and Epican Forte, in therapeutic proportions.
2. The method of claim 1 wherein Quercetin Glycoside is extracted from a plant source selected from the group of onions and apples.
3. The method of claim 1 wherein the dose of Quercetin is equivalent to between approximately 100 mg and 15 grams on a daily basis.
4. The method of claim 1 wherein the dose of Quercetin is equivalent to between approximately 1 grams and 10 grams on a daily basis.
5. The method of claim 1 wherein the dose of Quercetin is repeated daily.
6. The method of claim 1, wherein the Quercetin is administered to a human as part of foods, drinks, health bars, bread or cereals.
7. The method of claim 1 wherein Epican Forte is administered in daily amounts indicated in Table 1.
8. A composition for use in treatment of hypertension in a patient susceptible or suffering from hypertension or its side effects, comprising of Quercetin or Quercetin Glycoside and Epican Forte in therapeutic amounts.
9. The composition of claim 8 wherein Quercetin Glycoside is extracted from a plant source selected from the group of onions and apples.
10. The composition of claim 8 wherein the dose of Quercetin or Quercetin Glycoside is equivalent to between approximately 100 mg and 15 grams on a daily basis.
11. The composition of claim 8 wherein the dose of Quercetin or Quercetin Glycoside is equivalent to between approximately 1 grams and 10 grams on a daily basis.
12. The composition of claim 8 wherein the dose of Quercetin or Quercetin Glycoside is repeated daily.
13. The composition of claim 8, wherein the Quercetin or Quercetin Glycoside is administered to a human as part of foods, drinks, health bars, bread or cereals.
14. The composition of claim 8 wherein Epican Forte is administered in daily amounts indicated in Table 1.
US10/449,828 2003-05-30 2003-05-30 Novel composition and method for the treatment of hypertension Abandoned US20040242504A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US10/449,828 US20040242504A1 (en) 2003-05-30 2003-05-30 Novel composition and method for the treatment of hypertension
CNA200480015142XA CN1798555A (en) 2003-05-30 2004-05-26 Novel composition and method for the treatment of hypertension
MXPA05012859A MXPA05012859A (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof.
AU2004245017A AU2004245017A1 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
CA002524381A CA2524381A1 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
PCT/US2004/016902 WO2004108127A1 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
ZA200509139A ZA200509139B (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
RU2005141423/13A RU2005141423A (en) 2003-05-30 2004-05-26 FOOD COMPOSITIONS AND METHOD FOR INHIBITING THEIR REDUCTION OF SMOOTHMUSCEL CELL
EP04753685A EP1628658A4 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
JP2006533488A JP2007520449A (en) 2003-05-30 2004-05-26 Nutritional composition and method for inhibiting smooth muscle cell contraction using the same
BRPI0410868-0A BRPI0410868A (en) 2003-05-30 2004-05-26 nutritional composition and method of inhibiting smooth muscle cell contraction with the same
YUP-2005/0887A RS20050887A (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
KR1020057022975A KR20060014067A (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US10/855,111 US7166309B2 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
UAA200511385A UA82879C2 (en) 2003-05-30 2004-05-26 Method of inhibiting smooth muscle cell contraction
NO20056193A NO20056193L (en) 2003-05-30 2005-12-27 Nutritional preparation and methods for inhibiting smooth muscle cell contraction
US11/672,268 US20070141171A1 (en) 2003-05-30 2007-02-07 Novel composition and method for the treatment of hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/449,828 US20040242504A1 (en) 2003-05-30 2003-05-30 Novel composition and method for the treatment of hypertension

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/855,111 Continuation-In-Part US7166309B2 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US11/672,268 Continuation US20070141171A1 (en) 2003-05-30 2007-02-07 Novel composition and method for the treatment of hypertension

Publications (1)

Publication Number Publication Date
US20040242504A1 true US20040242504A1 (en) 2004-12-02

Family

ID=33451875

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/449,828 Abandoned US20040242504A1 (en) 2003-05-30 2003-05-30 Novel composition and method for the treatment of hypertension
US10/855,111 Expired - Fee Related US7166309B2 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US11/672,268 Abandoned US20070141171A1 (en) 2003-05-30 2007-02-07 Novel composition and method for the treatment of hypertension

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/855,111 Expired - Fee Related US7166309B2 (en) 2003-05-30 2004-05-26 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US11/672,268 Abandoned US20070141171A1 (en) 2003-05-30 2007-02-07 Novel composition and method for the treatment of hypertension

Country Status (5)

Country Link
US (3) US20040242504A1 (en)
CN (1) CN1798555A (en)
RS (1) RS20050887A (en)
UA (1) UA82879C2 (en)
ZA (1) ZA200509139B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104042968A (en) * 2014-06-24 2014-09-17 王秀红 Traditional Chinese medicinal composition for treating acute renal failure

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070262073A1 (en) * 2005-09-01 2007-11-15 David Naylor Modular heated cover
US20070265211A1 (en) * 2006-05-12 2007-11-15 Matthias Rath Novel composition and method effective in inhibiting the atherogenic process
WO2015094767A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for maintaining or increasing bodyweight using decaffeinated green tea extract
CA2955386A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3171882A1 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using a cll-1 chimeric antigen receptor
CN105497006A (en) * 2015-12-15 2016-04-20 武汉华纳联合药业有限公司 Application of flavonol compounds and flavanol compounds
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840966A (en) * 1987-03-03 1989-06-20 Mitsui Norin Co., Ltd. Method of treating hypertension
US6054128A (en) * 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840966A (en) * 1987-03-03 1989-06-20 Mitsui Norin Co., Ltd. Method of treating hypertension
US6054128A (en) * 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104042968A (en) * 2014-06-24 2014-09-17 王秀红 Traditional Chinese medicinal composition for treating acute renal failure

Also Published As

Publication number Publication date
UA82879C2 (en) 2008-05-26
US20050019429A1 (en) 2005-01-27
US7166309B2 (en) 2007-01-23
CN1798555A (en) 2006-07-05
US20070141171A1 (en) 2007-06-21
ZA200509139B (en) 2007-01-31
RS20050887A (en) 2007-09-21

Similar Documents

Publication Publication Date Title
US20070141171A1 (en) Novel composition and method for the treatment of hypertension
Kumar et al. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome
Hosseini et al. A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients
Zibadi et al. Oral administration of purple passion fruit peel extract attenuates blood pressure in female spontaneously hypertensive rats and humans
US20070088078A1 (en) Methods for managing adipocyte fat accumulation
US20220193100A1 (en) Composition containing glucoraphanin and use thereof
JP2015514131A (en) Use of arabinogalactan in combination with the nutritional compounds dihydroquercetin (taxifolin) and dihydroquercetin (taxifolin) to reduce and control cardiovascular metabolic risk factors associated with metabolic syndrome and hypercholesterolemia
US20050053674A1 (en) Pharmaceutical composition and method for retardation of the progression of atherosclerosis
RU2346685C2 (en) Compositions and methods for prevention and treatment of human prostate cancer
Roorda Therapeutic interventions against accumulation of advanced glycation end products (AGEs)
Hashim Fauzy et al. Piper sarmentosum leaves aqueous extract attenuates vascular endothelial dysfunction in spontaneously hypertensive rats
Wang et al. Recent advances in the effects of dietary polyphenols on inflammation in vivo: Potential molecular mechanisms, receptor targets, safety issues, and uses of nanodelivery system and polyphenol polymers
Ho et al. Effects of commercial citrate-containing juices on urolithiasis in a Drosophila model
Houston Treatment of hypertension with nutrition and nutraceutical supplements: Part 2
Rethinam et al. Health benefits of coconut water
KR20190058346A (en) Composition comprising chp (cyclo-his pro) for preventing, improving or treating of bone loss related disease
CA2524381A1 (en) Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
WO2004105679A2 (en) Use of a nutritional composition for treating hypertension
JP2008509877A (en) Pharmaceutical formulation for suppressing cardiovascular disease, usually containing vitamin C, magnesium, green tea extract
Cesarone et al. Improvement in circulation and in cardiovascular risk factors with a proprietary isotonic bioflavonoid formula OPC-3®
Blacks Effects of Raspberry Consumption on Angiotensin II-induced Hypertension and Expression of Antioxidant and Pro-oxidant Enzymes in the Brain of Rats
US20210212973A1 (en) Cardioprotective amino acid formulation
JP2005210909A (en) Whitening health food and drink
KR100572620B1 (en) Composition comprising protocathechualdehyde and its pharmaceutically acceptable salt for prevention and treatment of diabetic complication
ZA200609169B (en) Nutritional composition for increasing creatine uptake in skeletal muscle

Legal Events

Date Code Title Description
AS Assignment

Owner name: RATH, MATTHIAS, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IVANOV, VADIM;IVANOVA, SVETLANA;ROOMI, WAHID M.;AND OTHERS;REEL/FRAME:018468/0757;SIGNING DATES FROM 20060922 TO 20060925

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION